iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia-Reference-Cited by-同舟云学术

iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia

Published:2012-04 Issue:2 Volume:234 Page:499-505
ISSN:0014-4886
Container-title:Experimental Neurology
language:en
Short-container-title:Experimental Neurology

Author:

Lehnert Stefan,Jesse Sarah,Rist Wolfgang,Steinacker Petra,Soininen Hilkka,Herukka Sanna-Kaisa,Tumani Hayrettin,Lenter Martin,Oeckl Patrick,Ferger Boris,Hengerer Bastian,Otto Markus

Funder

Landesstiftung Baden-Württemberg

Kuopio University Hospital

University of Eastern Finland

Publisher

Elsevier BV

Subject

Developmental Neuroscience,Neurology

Reference51 articles.

1. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins;Anderson;Mol. Cell. Proteomics,2006

2. Limits of the ‘Mini-Mental State’ as a screening test for dementia and delirium among hospital patients;Anthony;Psychol. Med.,1982

3. Overexpression of human apolipoprotein B-100 induces severe neurodegeneration in transgenic mice;Bereczki;J. Proteome Res.,2008

4. Sharpening the boundaries of Parkinson-associated dementia: recommendation for a neuropsychological diagnostic procedure;Bothe;J. Neural. Transm.,2010

5. Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt–Jakob disease;Brechlin;Proteomics,2008

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cerebrospinal fluid protein biomarkers in Parkinson's disease;Clinica Chimica Acta;2024-03

2. Role of Apolipoproteins in Neurodegenerative Diseases;Journal of Gazi University Health Sciences Institute;2023-12-31

3. Elucidating distinct molecular signatures of Lewy body dementias;Neurobiology of Disease;2023-11

4. Pre-clinical Aspects and Contemporary Treatments of Parkinson’s Disease;CNS & Neurological Disorders - Drug Targets;2023-10-06

5. HDL Accessory Proteins in Parkinson’s Disease—Focusing on Clusterin (Apolipoprotein J) in Regard to Its Involvement in Pathology and Diagnostics—A Review;Antioxidants;2022-03-09